IRX4 activators belong to a distinctive chemical class with profound implications for modulating cellular processes. At the heart of their functionality lies a unique mechanism targeting the insulin gene enhancer protein, ISL1-related homeobox 4 (IRX4). This protein, a member of the Iroquois homeobox gene family, plays a pivotal role in cardiac development and the regulation of cardiac ion channels. IRX4 activators act as small molecules that interact with IRX4, prompting conformational changes or alterations in its activity. This interaction, at a molecular level, can influence gene expression patterns and intracellular signaling cascades related to cardiac physiology. The chemical class of IRX4 activators, therefore, holds promise in unraveling the intricate network of molecular events governing cardiac function, potentially offering insights into cardiac development, electrophysiology, and related cellular pathways.
The discovery and characterization of IRX4 activators mark a significant advancement in our understanding of cellular processes, particularly in the context of cardiac biology. By selectively modulating the activity of IRX4, these compounds provide researchers with a powerful tool to investigate the nuanced regulatory mechanisms orchestrating cardiac gene expression and function. This chemical class's potential extends beyond its immediate implications for cardiac research, as deciphering the intricacies of IRX4 activation could unveil broader insights into the functioning of homeobox genes and their roles in developmental and physiological processes across various tissues. The exploration of IRX4 activators, therefore, stands at the forefront of unraveling the complexities of molecular biology and holds promise for contributing to the broader landscape of scientific knowledge.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
GSK-3β inhibitor that indirectly activates IRX4 by modulating the Wnt signaling pathway. | ||||||
Purmorphamine | 483367-10-8 | sc-202785 sc-202785A | 1 mg 5 mg | $57.00 $184.00 | 18 | |
Sonic Hedgehog agonist indirectly activates IRX4 by modulating the Hedgehog signaling pathway. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor activates IRX4 indirectly through modulation of the TGF-β signaling pathway. | ||||||
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
γ-Secretase inhibitor activates IRX4 indirectly by modulating the Notch signaling pathway. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor blocker activates IRX4 indirectly through the regulation of the RAAS. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
cAMP analog and PKA activator directly activates IRX4 by modulating the PKA pathway. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
ERK activator indirectly activates IRX4 through the MAPK/ERK pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor activates IRX4 indirectly through modulation of the PI3K/AKT pathway. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
AKT activator directly activates IRX4 by modulating the PI3K/AKT pathway. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
NF-κB inhibitor activates IRX4 indirectly through modulation of the NF-κB pathway. | ||||||